The use of Cannabidiol in the treatment of Alzheimer`s Disease: What are the main pharmacological effects attributed to Cannabidiol relevant to the treatment of Alzheimer`s Disease?
DOI:
https://doi.org/10.33448/rsd-v15i4.50895Keywords:
Cannabis, Alzheimer Disease, Treatment, Neurodegenerative Diseases.Abstract
Neurodegenerative diseases represent one of the major global public health challenges, especially due to population aging. Among them, Alzheimer’s disease (AD) stands out for its high prevalence and severe impact on the quality of life of patients and their families. Characterized by the progressive loss of neurons and the abnormal accumulation of β-amyloid (Aβ) and Tau proteins, AD involves complex mechanisms of neuroinflammation, oxidative stress, and synaptic dysfunction. In this context, cannabidiol (CBD), a non-psychoactive phytocannabinoid derived from Cannabis sativa, has attracted growing scientific interest due to its anti- inflammatory, antioxidant, and neuroprotective properties. This study aims to analyze the main pharmacological effects and mechanisms of action of CBD in the treatment of Alzheimer’s disease through a scoping review conducted in the Google Scholar and PubMed databases, covering publications from 2010 to 2025. The results show that CBD acts on multiple molecular targets such as CB1, CB2, PPARγ, TRPV1, 5-HT1A, and GPR55, promoting a reduction in neuroinflammation, inhibition of the GSK-3β enzyme, activation of the Wnt/β-catenin pathway, decreased Aβ production and Tau phosphorylation, as well as improved synaptic homeostasis. Although there are still gaps regarding optimal dosage, long-term safety, and standardized clinical protocols, current evidence indicates that CBD is a promising and safe therapeutic alternative for managing Alzheimer’s disease, potentially slowing its progression and improving patients’ quality of life.
References
Abate, G., Uberti, D., & Tambaro, S. (2021). Potential and limits of cannabinoids in Alzheimer’s disease therapy. Biology, 10(6), 542. https://doi.org/10.3390/biology10060542
Assis, C. R. C., & Camacho, A. C. L. F. (2016). Qualidade de vida dos idosos com doença de Alzheimer: Uma revisão integrativa. Revista de Enfermagem UFPE On Line, 10(Supl. 6), 4959–4968.
Balachandran, P., ElSohly, M., & Khatri, H. (2021). Cannabidiol interactions with medications. Journal of Clinical Medicine, 10(5), 989. https://doi.org/10.3390/jcm10050989
Bhunia, S., et al. (2022). Cannabidiol for neurodegenerative disorders: A comprehensive review. Frontiers in Pharmacology, 13, 804613. https://doi.org/10.3389/fphar.2022.804613
Brito, M. (2023). Impacto dos canabinoides no tratamento do Alzheimer. Brazilian Journal of Health Review, 6(1), 1–10.
Coles, M., et al. (2022). Cannabinoids in Alzheimer’s disease: Therapeutic potential and clinical evidence. Journal of Alzheimer’s Disease.
European Medicines Agency. (2025). Epidyolex (cannabidiol): Product information. https://www.ema.europa.eu
Fernandes, J. M. B., Vieira, L. T., & Castelhano, M. V. C. (2023). Revisão narrativa enquanto metodologia científica significativa. REDES, 3(1), 1–7.
Ferreira, A. P. M., et al. (2016). Doença de Alzheimer. Mostra Interdisciplinar do Curso de Enfermagem, 2(2).
Florian, J., et al. (2025). Cannabidiol and liver enzyme level elevations. JAMA Internal Medicine.
Gonçalves, G. (2019). O uso do canabidiol para combater doenças neurodegenerativas. Medicina S/A.
Hermush, V., et al. (2022). Effects of cannabidiol oil in dementia. Frontiers in medicine, 9, 951889.
Hou, Y., et al. (2019). Ageing as a risk factor. Nature Reviews Neurology, 15(10), 565–581.
Hickey, J. P., et al. (2024). Targets for Alzheimer’s treatment. Genes, 15(1), 37.
José Luiz, M., et al. (2012). Canabinoides e aplicações terapêuticas. Revista Brasileira de Neurologia.
Kovacs, G. G. (2018). Neurodegenerative diseases classification. Handbook of Clinical Neurology.
Laprairie, R. B., et al. (2015). Cannabidiol as CB1 modulator. British Journal of Pharmacology, 172(20), 4790–4805.
Madeo, G., et al. (2023). Cannabidiol toxicity update. Pharmaceuticals, 16(3).
Oliveira, H. A., & Lima, E. F. (2022). Propriedades do óleo de canabidiol. Instituto Federal Goiano.
Pereira, A. S., et al. (2018). Metodologia científica. UFSM.
Risemberg, R. I. C., et al. (2026). Importância da metodologia científica. E-Acadêmica.
Raïch, I., et al. (2025). Cannabidiol and Alzheimer’s. Alzheimer’s Research & Therapy.
Rodrigues, G. (2024). Canabidiol e neuroproteção. Brazilian Journal of Health Review.
Rother, E. T. (2007). Revisão narrativa. Acta Paulista de Enfermagem.
Santos, R., & Vasconcelos, B. F. M. (2020). Cannabis medicinal no Brasil. Jota.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Julia Grazielly dos Santos, Jean Colacite
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
